EMA Authorised: Kengrexal (cangrelor) — Chiesi Farmaceutici S.p.A.

View source ↗

Summary

The European Medicines Agency authorised Kengrexal (cangrelor) for acute coronary syndrome and during vascular surgical procedures, with Chiesi Farmaceutici S.p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Syndrome

Drugs mentioned

• Kengrexal (cangrelor)

Snippet

Status: Authorised. Therapeutic area: Acute Coronary Syndrome;Vascular Surgical Procedures. MAH: Chiesi Farmaceutici S.p.A.. Decision date: 10/02/2026